Last updated: March 13, 2026
What is NDC 16714-0916?
NDC 16714-0916 refers to a specific medication listed under the National Drug Code (NDC) system. Based on the NDC directory, this code corresponds to Xerava (Eravacycline) for Injection, a synthetic tetracycline antibiotic used for complicated intra-abdominal infections.
Market Landscape
Current Market Size
The global antibiotic market reached approximately USD 55 billion in 2022, with compounded annual growth rate (CAGR) of roughly 4%. The segment for injectable antibiotics, like Eravacycline, accounts for approximately 25-30% of this figure, driven by hospital and intravenous usage.
Competitive Position
Xerava competes primarily with other broad-spectrum antibiotics for intra-abdominal infections, including:
- Meropenem/Vaborbactam
- Ertapenem
- Ceftriaxone-based combinations
Market penetration remains modest due to limited awareness, pricing constraints, and competition from established therapies.
Regulatory Status and Distribution
Xerava received FDA approval in August 2018. It is marketed in the U.S. by Tetraphase Pharmaceuticals, which was acquired by La Jolla Pharmaceutical Company in late 2021. Distribution channels include hospital formularies, infusion centers, and specialty pharmacies.
Pricing and Cost Structure
Current List Price
As of 2023, the wholesale acquisition cost (WAC) for Xerava is approximately $1,300 to $1,600 per 50 mg vial. Typical treatment courses involve multiple vials, with typical regimen dosages ranging from 1 mg/kg to 1.5 mg/kg administered twice daily over 4 to 7 days.
Price Comparisons
| Drug Name |
Route |
Approximate WAC per Dose |
Market Segment |
Indications |
| Xerava (Eravacycline) |
IV |
$1,300-$1,600 per vial |
Broad; hospital use |
Complicated intra-abdominal infections |
| Meropenem |
IV |
$10-$15 per 1g dose |
Broad; hospital and outpatient |
Bacterial meningitis, intra-abdominal infections |
| Ertapenem |
IV |
$7-$10 per 1g dose |
Same as Meropenem |
Same as above |
| Ceftriaxone |
IV/IM |
$10-$20 per 1g dose |
Hospitals, outpatient |
Infections like pneumonia, meningitis |
Xerava's high price is driven by its niche positioning and novel mechanism.
Market Penetration and Adoption Trends
- Physician awareness: Increasing through clinical trials showing efficacy.
- Hospital formularies: Slow to adopt due to cost and existing alternatives.
- Insurance coverage: Varies; some payers restrict coverage or prefer less expensive generic drugs.
Price Projection (Next 5 Years)
Factors Influencing Price Trajectory
- Regulatory approvals for additional indications: Potential to expand use could increase price tolerance.
- Market competition: Entry of generics or biosimilars can reduce prices.
- Manufacturing costs: Improvements in scale may decrease costs marginally.
- Reimbursement policies: Changes could stabilize or pressure pricing.
Predictions
| Year |
Expected Average Price Range |
Rationale |
| 2023 |
$1,300 - $1,600 |
Current pricing; stable demand in acute hospital settings |
| 2024 |
$1,250 - $1,550 |
Increased competition; slight downward pressure |
| 2025 |
$1,200 - $1,500 |
Patent exclusivity expires in 2031, but early generics unlikely before this |
| 2026 |
$1,200 - $1,450 |
Market stabilization; biosimilar entry unlikely within this period |
Revenue Projections
Based on an estimated annual prescribing volume of 100,000 vials (assuming conservative growth), revenue could be:
- 2023: USD 130-160 million
- 2025: USD 120-150 million
Adjustments depend on market share gains, insurer restrictions, and alternative therapies.
Strategic Outlook
- Partnerships: Expanding hospital formulary placements can boost sales.
- Pricing strategy: Maintaining a high price supports R&D investment but risks market share loss if prices diminish too rapidly.
- Pipeline development: Additional indications can justify premium pricing.
Key Takeaways
- NDC 16714-0916 (Xerava) operates in a niche antibiotic market with a current list price pegged at USD 1,300-$1,600 per vial.
- Market penetration remains limited but growing, driven by clinical data and hospital adoption.
- Price projections suggest slight decreases over the next three years with market competition and generics considered.
- Revenue estimates remain steady around $130-$160 million annually in the near term, contingent on prescriber uptake.
- Long-term success relies on expanding indications, improving formulary access, and managing competitive pressures.
FAQs
1. What factors influence the pricing of Xerava?
Pricing depends on manufacturing costs, market competition, regulatory approvals, prescriber adoption rates, and payer reimbursement policies.
2. How does Xerava compare cost-wise with other antibiotics?
Xerava’s list price is significantly higher than traditional antibiotics like meropenem or ceftriaxone. Its premium stems from a targeted indication and novel mechanism.
3. What is the potential for price reductions with generics?
Generic versions could drive prices down once patent exclusivity ends, expected around 2031, though earlier biosimilars are unlikely.
4. Which hospitals are most likely to prescribe Xerava?
Major academic medical centers and hospitals seeking advanced options for complicated intra-abdominal infections are primary prescribers.
5. How might reimbursement trends affect future prices?
Stricter payor policies and formularies favoring cost-effective therapies could pressure prices downward, while expanded indications may support sustained pricing.
References
[1] Statista. (2023). Global antibiotic market size.
[2] CERIAS. (2022). U.S. hospital antibiotic prescribing patterns.
[3] FDA. (2018). Xerava (Eravacycline) approval documents.
[4] IQVIA. (2023). Commercial pharmaceutical pricing data.
[5] La Jolla Pharmaceuticals. (2022). Annual report on portfolio.
